Drug Royalty Corporation Changes Its Name to DRI Capital

    TORONTO, Oct. 10 /CNW/ -- DRI Capital announced that after close to 15
years, it is retiring the name Drug Royalty Corporation and will now
officially be known as DRI Capital.
    DRI Capital is a privately held investment management company, focused on
the healthcare industry, with over US$1 billion under management.  DRI Capital
currently manages two funds:  the Royalty Monetization Fund and the Structured
Finance Fund.
    Its Royalty Monetization Fund acquires existing royalty streams at
competitive rates from companies, institutions and inventors.  DRI Capital is
a leader in monetizing royalties, having acquired over US$850 million in
royalty-based cash flows on commercialized products. In 2007 alone, DRI
Capital has deployed about US$450 million with royalty acquisitions on
products such as Enbrel, Flumist, Preotact and PEG-INTRON.
    Its Structured Finance Fund will soon close with approximately US$300
million in committed capital.  This Fund provides predominantly non-dilutive
financing for product acquisitions and launches, M & A, in-licensing, sales
force expansion and general working capital purposes to companies within the
healthcare industry.  The Fund invests in cash flow monetization structures
which can include debt and equity components, custom tailored to fit the needs
of clients.

For further information:

For further information: Golnar Khosrowshahi, DRI Capital,
+1-416-324-5707  or gk@dricapital.com

Organization Profile


More on this organization


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890